Home » Zogenix’s Fintepla Approved for Rare Form of Epilepsy
Zogenix’s Fintepla Approved for Rare Form of Epilepsy
The FDA has approved Zogenix’s Fintepla (fenfluramine) for seizures associated with Dravet syndrome, a rare form of epilepsy, in patients age 2 years and older.
The approval was based on the results of two clinical trials, in which patients treated with Fintepla had significantly greater reductions in seizures than those who received a placebo.
The FDA is requiring a boxed warning for the drug on the risk of heart disease and hypertension.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May